Introduction: In India since 2002,after the introduction of 18F-FDG for various clinical applications, different other PET radiopharmaceuticals have also been developed progressively. However, only a few of them make their place in routine clinical practices; partly because of stringent regulatory guidelines& facilities and also due to the physio-chemical properties of radionuclide itself. The most common radionuclides for PET radiopharmaceuticals include 18F, 68Ga,11C, 13N, 15O, 64Cu, and 82Rb. AIMS and Objective: This study aims to provide an overview of PET radiopharmaceuticals that are commonly synthesized either in-house (onsite) or in commercial distribution centers after fulfilling the regulatory and quality aspects. Result and Discussion: 18F radionuclide as PET radiopharmaceutical has made its place inevitable in oncology, Cardiology, and Neurology. Apart from this, various other PET radiopharmaceuticals like 68Ga, 11C, 64Cu, 13N, etc. play a vital role in the management of other malignancies like carcinoma prostate, neuroendocrine tumors, etc. PET radiopharmaceuticals are the basis for molecular imaging and their utilization for appropriate clinical indications in diseases. Conclusion: This review article will provide a basic understanding of various PET radiopharmaceuticals including their synthesis, properties, and clinical uses among physicians & technologists. Most of the PET radiopharmaceuticals are being used for diagnosing and treatment evaluations of various oncology and others diseases patients.
